Status:
WITHDRAWN
CMAB vs IMAB in Metastatic Prostate Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary e...
Eligibility Criteria
Inclusion
- Histological diagnosis of D2 of Adenocarcinoma,
- Naivety to treatment
- Valuable bone metastasis
Exclusion
- Hematological, liver or renal toxicity Grade IV
- Severe and active infections
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00255268
Start Date
August 1 2004
Last Update
August 28 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Metepec, Mexico
2
Research Site
Mexico City, Mexico